A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma
- PMID: 7804974
- DOI: 10.1002/1097-0142(19950101)75:1<34::aid-cncr2820750108>3.0.co;2-0
A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma
Abstract
Background: In a Phase II trial, surgical adjuvant active specific immunotherapy using a live vaccinia virus-augmented allogeneic polyvalent melanoma cell lysate, vaccinia melanoma oncolysate (VMO), produced a significant disease free interval (DFI) in patients with International Union Against Cancer Stage II melanoma with positive lymph nodes. Therefore, a Phase III randomized prospective, double-blind, multiinstitutional, surgical adjuvant VMO trial was performed to determine the efficacy of VMO to increase the DFI and the overall survival in this group of patients with Stage II disease.
Methods: Two hundred and fifty patients with Stage II melanoma were divided into two postsurgical groups. One group received VMO (total protein equals 2 mg/ml) and the other received the placebo of live vaccinia vaccine virus (V) (10(5.4) TCID50/ml), an adjuvant component of the VMO. Patients initially received these biologics once a week for 13 weeks and then once every 2 weeks for an additional 39 weeks or until recurrence. All surviving patients have been followed for at least 30 months.
Results: Statistical analysis of survival data (n = 217) for this first interim analysis shows that there is no statistically significant (P = 0.99) increase in DFI of patients treated with VMO (n = 104) when compared with V (n = 113). The median DFI is 38.0 months for patients treated with VMO and 37.0 months for patients treated with V. At 2- and 4-year intervals, 70 and 38%, respectively, of patients treated with VMO vs. 66 and 36%, respectively, of patients treated with V were free of melanoma. The median overall survival is not available because the patients treated with VMO have not yet reached the 50% mark and the median overall survival is 45.0 months for patients treated with V. At 2- and 4-year intervals, 70 and 38%, respectively, of VMO-treated patients survived when compared with 66 and 36%, respectively, of patients treated with V. Although the overall survival of patients treated with VMO is not statistically significant (P = 0.88) at this point, there is an increasing trend in the overall survival of patients treated with VMO; a 10% increase at the 4-year time point. Moreover, in the subset analysis, VMO-treated male patients (n = 63) showed a 17% improvement in survival at 4-year time point when compared with male patients treated with V (n = 67) (P = 0.19) at the same time point and male patients (n = 20) between the ages of 44 and 57 having 1-5 positive lymph nodes showed a 37% difference in overall survival at the 4-year time point when compared with those patients treated with V (n = 18) (P = 0.13) at the same time point.
Conclusion: In this first interim analysis, active specific immunotherapy with VMO vs. V showed no difference in the disease free interval or overall survival. Subset analyses likewise showed no significant differences in outcome but the data suggest a potential difference in immunoreactivity between male and female patients with melanoma that awaits further follow up and may merit further investigation.
Similar articles
-
Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.J Am Coll Surg. 1998 Jul;187(1):69-77; discussion 77-9. doi: 10.1016/s1072-7515(98)00097-0. J Am Coll Surg. 1998. PMID: 9660028 Clinical Trial.
-
Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial.Ann Surg Oncol. 1996 Mar;3(2):110-7. doi: 10.1007/BF02305788. Ann Surg Oncol. 1996. PMID: 8646509 Clinical Trial.
-
Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial.Ann Surg. 1997 Aug;226(2):198-206. doi: 10.1097/00000658-199708000-00012. Ann Surg. 1997. PMID: 9296514 Free PMC article. Clinical Trial.
-
Active specific immunotherapy with vaccinia melanoma oncolysate.Mt Sinai J Med. 1992 May;59(3):227-33. Mt Sinai J Med. 1992. PMID: 1318507 Review.
-
Active specific adjuvant immunotherapy with vaccinia melanoma oncolysate.Ann Plast Surg. 1992 Jan;28(1):108-9. doi: 10.1097/00000637-199201000-00027. Ann Plast Surg. 1992. PMID: 1642396 Review.
Cited by
-
Utility of cell-based vaccines as cancer therapy: Systematic review and meta-analysis.Hum Vaccin Immunother. 2024 Dec 31;20(1):2323256. doi: 10.1080/21645515.2024.2323256. Epub 2024 Mar 27. Hum Vaccin Immunother. 2024. PMID: 38544385 Free PMC article.
-
Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review.Cancer Biol Med. 2023 Aug 23;20(9):646-61. doi: 10.20892/j.issn.2095-3941.2023.0202. Cancer Biol Med. 2023. PMID: 37615308 Free PMC article. Review.
-
A systematic analysis on the clinical safety and efficacy of onco-virotherapy.Mol Ther Oncolytics. 2021 Oct 5;23:239-253. doi: 10.1016/j.omto.2021.09.008. eCollection 2021 Dec 17. Mol Ther Oncolytics. 2021. PMID: 34761104 Free PMC article.
-
Vaccine Therapies for Cancer: Then and Now.Target Oncol. 2021 Mar;16(2):121-152. doi: 10.1007/s11523-020-00788-w. Epub 2021 Jan 29. Target Oncol. 2021. PMID: 33512679 Free PMC article. Review.
-
Long non-coding RNA ZEB1-AS1 indicates poor prognosis and promotes melanoma progression through targeting miR-1224-5p.Exp Ther Med. 2019 Jan;17(1):857-862. doi: 10.3892/etm.2018.7005. Epub 2018 Nov 23. Exp Ther Med. 2019. PMID: 30651872 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical